Montana Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• FDA Update: Agency Approves First Oral PCSK9 Inhibitor to Treat High Cholesterol
  The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to lower LDL cholesterol in adults with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
• API-CAT Analysis: Recurrent VTE Uncommon, Associated With Poor Short-Term Survival
  Recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival among patients with cancer-associated thrombosis on extended apixaban therapy after at least six months of anticoagulation treatment, according to a post-hoc analysis of the API-CAT trial published July 13 in Circulation.
• Protein Intake and Cardiovascular Health: Separating Signal From Noise
  Media attention to protein has increased and resulted in significant scrutiny. Many individuals are unsure of how much protein to consume and whether higher intakes, like those recommended for exercise, are safe for cardiovascular health.
• ACC CardiaCast: Treatment of ASCVD Risk: From Lifestyle to Advanced Therapies
  This episode of CardiaCast will feature a discussion on the treatment of atherosclerotic cardiovascular disease (ASCVD) risk – from lifestyle to advanced therapies, led by Dr. Maya Safarova.
• ACC CardiaCast: The What, Who, When and Why of Screening of UACR
  In this first episode of The Increasing Role of Urine Albumin-Creatinine Ratio (UACR) in Cardiovascular Care series, Dr. Ankeet Bhatt interviews Dr. Katherine Tuttle on UACR, its role in kidney disease, and the importance of screening.